PD-1 pathway inhibitors are currently approved by the Food and Drug Administration (FDA) for the treatment of several solid tumors including melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), urothelial carcinoma, and head and neck cancer. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.